Hindustan Laboratories Limited has filed its Draft Red Herring Prospectus with SEBI for a proposed initial public offering.
The IPO comprises a fresh issue of up to 5,000,000 equity shares and an offer for sale of up to 9,100,000 equity shares, aggregating to a total of up to 14,100,000 equity shares of face value ₹10 each. The promoters of the company are Rajesh Vasantray Doshi, Kunjal C. Dedhia and Krishiv Rajesh Doshi.
According to the DRHP, the company plans to use the net proceeds from the fresh issue to fund working capital requirements and general corporate purposes.
Hindustan Laboratories manufactures generic medicines supplied mainly to government institutions under B2G arrangements. Its product portfolio includes formulations across several therapeutic categories catering to both acute and chronic conditions.
The company supplied its products across 27 states and Union Territories during FY25 and the six months ended September 30, 2025. The equity shares are proposed to be listed on BSE and NSE. Choice Capital Advisors Private Limited is the book running lead manager.
